Patents by Inventor Shuichi Nakatsuru
Shuichi Nakatsuru has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9187557Abstract: The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.Type: GrantFiled: January 23, 2014Date of Patent: November 17, 2015Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
-
Patent number: 9139655Abstract: The present invention relates to an antibody or a fragment thereof which is capable of binding to a Frizzled homologue 10 (FZD10) protein, such as a mouse monoclonal antibody, a chimeric antibody and a humanized antibody. Also, the present invention relates to a method for treating and/or preventing FZD10-associated disease; a method for diagnosis or prognosis of FZD10-associated disease; and a method for in vivo imaging of FZD10 in a subject.Type: GrantFiled: June 12, 2012Date of Patent: September 22, 2015Assignee: ONCOTHERAPY SCIENCE, INC.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru, Keigo Endo
-
Patent number: 9120842Abstract: It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.Type: GrantFiled: May 23, 2013Date of Patent: September 1, 2015Assignee: ONCO THERAPY SCIENCE, INC.Inventors: Yasuharu Nishimura, Yoshiaki Ikuta, Shuichi Nakatsuru
-
Publication number: 20140228238Abstract: The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.Type: ApplicationFiled: January 23, 2014Publication date: August 14, 2014Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: Yusuke NAKAMURA, Toyomasa KATAGIRI, Shuichi NAKATSURU
-
Patent number: 8795976Abstract: The present application provides novel human gene B7330N whose expression is markedly elevated in breast cancers. The gene and polypeptide encoded by the gene can be used, for example, in the diagnosis of breast cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of breast cancer.Type: GrantFiled: July 26, 2006Date of Patent: August 5, 2014Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
-
Patent number: 8771963Abstract: In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, ECT2, CDC45L and DKK1 are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells.Type: GrantFiled: September 27, 2011Date of Patent: July 8, 2014Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
-
Publication number: 20140186381Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.Type: ApplicationFiled: January 21, 2014Publication date: July 3, 2014Applicant: Oncotherapy Science, Inc.Inventors: Hideaki Tahara, Takuya Tsunoda, Masabumi Shibuya, Shuichi Nakatsuru
-
Publication number: 20140134637Abstract: The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified.Type: ApplicationFiled: April 22, 2011Publication date: May 15, 2014Applicant: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Yoichi Furukawa, Ryuji Hamamoto, Shuichi Nakatsuru
-
Patent number: 8709731Abstract: Described herein are antibodies and antibody fragments capable of treating or preventing cancers associated with the over-expression and/or up-regulation of DKK1. Also disclosed are methods of treating or preventing cancer using the antibody and methods and kits utilized to diagnosing cancer. The herein described products and methods find utility in the context of a variety of cancers, such as pancreatic cancer, gastric cancer, liver cancer, prostate cancer, breast cancer, cervical cancer, bile duct cancer, lung cancer and esophageal cancer.Type: GrantFiled: August 21, 2008Date of Patent: April 29, 2014Assignee: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
-
Patent number: 8685641Abstract: Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. The present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. Specifically, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers.Type: GrantFiled: June 28, 2012Date of Patent: April 1, 2014Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
-
Patent number: 8673548Abstract: The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.Type: GrantFiled: August 10, 2007Date of Patent: March 18, 2014Assignee: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
-
Patent number: 8663647Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.Type: GrantFiled: August 3, 2012Date of Patent: March 4, 2014Assignee: Oncotherapy Science, Inc.Inventors: Hideaki Tahara, Takuya Tsunoda, Masabumi Shibuya, Shuichi Nakatsuru
-
Patent number: 8614176Abstract: The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors comprising these peptides. The peptides of the present invention can also be used as vaccines.Type: GrantFiled: October 13, 2010Date of Patent: December 24, 2013Assignee: OncoTherapy Science, Inc.Inventors: Hideaki Tahara, Takuya Tsunoda, Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
-
Publication number: 20130288363Abstract: It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.Type: ApplicationFiled: May 23, 2013Publication date: October 31, 2013Inventors: Yasuharu NISHIMURA, Yoshiaki IKUTA, Shuichi NAKATSURU
-
Publication number: 20130230521Abstract: The present invention relates to an antibody or a fragment thereof which is capable of binding to a Frizzled homologue 10 (FZD10) protein, such as a mouse monoclonal antibody, a chimeric antibody and a humanized antibody. Also, the present invention relates to a method for treating and/or preventing FZD10-associated disease; a method for diagnosis or prognosis of FZD10-associated disease; and a method for in vivo imaging of FZD10 in a subject.Type: ApplicationFiled: June 12, 2012Publication date: September 5, 2013Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru, Keigo Endo
-
Patent number: 8470968Abstract: It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.Type: GrantFiled: September 23, 2011Date of Patent: June 25, 2013Assignee: Onco Therapy Science, Inc.Inventors: Yasuharu Nishimura, Yoshiaki Ikuta, Shuichi Nakatsuru
-
Publication number: 20130084578Abstract: Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. Also described are methods of treating and preventing breast cancer and breast cancer metastasis as well as methods of assessing the prognosis of a breast cancer subject and the efficacy of a breast cancer therapy. In one embodiment, the diagnostic method involves determining the expression level of ZNFN3A1, a gene whose expression is markedly elevated in breast cancers, that therefore can be used to discriminate between BRC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of BRC, methods of treating BRC and method for vaccinating a subject against BRC.Type: ApplicationFiled: March 30, 2011Publication date: April 4, 2013Applicant: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Yoichi Furukawa, Shuichi Nakatsuru
-
Patent number: 8354223Abstract: The present invention relates to methods for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of VEGFR1 by SMYD3. The invention further provides methods and pharmaceutical compositions for treating and preventing colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified.Type: GrantFiled: June 13, 2008Date of Patent: January 15, 2013Assignee: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Yoichi Furukawa, Ryuji Hamamoto, Shuichi Nakatsuru
-
Publication number: 20130011933Abstract: Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. The present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. Specifically, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers.Type: ApplicationFiled: June 28, 2012Publication date: January 10, 2013Applicant: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
-
Publication number: 20120294877Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.Type: ApplicationFiled: August 3, 2012Publication date: November 22, 2012Applicant: Oncotherapy Science, Inc.Inventors: Hideaki Tahara, Takuya Tsunoda, Masabumi Shibuya, Shuichi Nakatsuru